FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
latest-news-card-1
Human Drugs

FDA Broadens Use of Amgens Repatha

FDA expands the approved use of Amgens cholesterol-lowering drug Repatha (evolocumab) to include adults at increased risk of major adverse cardiovascu...

latest-news-card-1
Biologics

Argenx Plans sBLA for Vyvgart in Myasthenia Gravis

Argenx says it will seek expanded approval for Vyvgart (efgartigimod alfa-fcab) to include adults with acetylcholine receptor antibody seronegative ge...

latest-news-card-1
Human Drugs

FDA Moves to Daily Drug Adverse Event Data

FDA is now publishing drug safety data on a daily basis, a shift the agency says will give the public faster access to information about adverse event...

latest-news-card-1
Human Drugs

Vanda Urges Makary to Intercede in Generic Dispute

Vanda Pharmaceuticals urges FDA commissioner Marty Makary to reconsider a recent agency decision upholding approvals of two generic versions of Hetlio...

Medical Devices

AdvaMed Urges FDA/CMS Alignment on Breakthrough Devices

AdvaMed and other device stakeholders urge the Centers for Medicare & Medicaid Services to overhaul how it covers new device technologies, warning tha...

latest-news-card-1
Human Drugs

Boston Scientific Recalls Defective Stent System

Boston Scientific recalls (Class 1) its Carotid Wallstent Monorail Endoprosthesis due to a manufacturing defect that created an inner lumen smaller th...

latest-news-card-1
Human Drugs

FDA 483 Shows GMP Troubles at Plant Making Eylea

A new Form FDA-483 cites significant GMP issues at the plant that makes Regenerons Eylea HD (aflibercept), delaying review of two related regulatory s...

latest-news-card-1
Medical Devices

FDA Clears Signos OTC Glucose Monitor

FDA clears a Signos 510(k) for what the company says is the first over-the-counter glucose monitoring system designed specifically for weight manageme...

latest-news-card-1
Human Drugs

Stealth Gets Expedited Review on NDA Resubmission

FDA accepts for review a Stealth BioTherapeutics NDA resubmission for elamipretide for treating Barth syndrome, with the agency agreeing to expedite i...

latest-news-card-1
Human Drugs

Nicox Plans NDA for Glaucoma Drug

Nicox plans an NDA early next year after new data from its DENALI Phase 3 study of glaucoma therapy NCX 470 showed promising results compared to stand...